MicroPort CardioFlow Completes Major Acquisition to Expand into Cardiac Rhythm Management

An update from MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) is now available.

MicroPort CardioFlow Medtech Corporation has completed the acquisition of MicroPort Cardiac Rhythm Management Limited and its subsidiaries, which have now become indirect subsidiaries of the group. The deal, structured as a very substantial acquisition and connected transaction involving the issue of new shares under a specific mandate, significantly reshapes the company’s shareholding structure, with total shares rising from about 2.41 billion to 6.37 billion and diluting existing public shareholders while bringing in the original shareholders of the target company and strengthening the stake held by its major shareholder, MicroPort. The merger expands MicroPort CardioFlow’s business from structural heart interventions into cardiac rhythm management, establishing a diversified platform across the “Total Cardio” field, broadening its global market presence, and enhancing competitiveness and risk resilience as it seeks to integrate technologies and resources to offer comprehensive heart failure management solutions.

The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.

More about MicroPort CardioFlow Medtech Corp.

MicroPort CardioFlow Medtech Corporation is a Hong Kong-listed medical device company focused on the interventional treatment of structural heart diseases. Its product portfolio targets the cardiovascular sector and, with recent expansion, aims to build a diversified “Total Cardio” platform covering a broader spectrum of cardiac diagnosis and therapy solutions for global markets.

Average Trading Volume: 4,770,836

Technical Sentiment Signal: Sell

Current Market Cap: HK$2.61B

See more insights into 2160 stock on TipRanks’ Stock Analysis page.